NCT06142955Recruiting
Transcranial Magnetic Stimulation (TMS) to Treat Depression in Autism Spectrum Disorder
Neuromodulation for Depression in Autism Spectrum Disorder
Source: ClinicalTrials.gov · Last updated 16 Jul 2026
Brief summary (registry, in English)
This study will assess clinical and behavioral measures along with electroencephalogram (EEG), event-related potentials (ERPS), and eye-tracking (ET) prior to and following a single intermittent Theta Burst Stimulation (iTBS) session to provide preliminary insight into the potential of TMS as an intervention for depression in individuals with Autism Spectrum Disorder (ASD).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 15 Nov 2023
- Start date
- 30 Apr 2024
- Primary completion date
- Feb 2027
- Lead sponsor
- Yale University
- Diseases
- Autism
- NCT number
- NCT06142955
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 30 Apr 2024 to the primary completion date, Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants taking prescription medications that may affect cognitive processes under study.
- Participants who have taken alcohol or recreational drugs within the preceding 24 hours prior to the scheduled study visit as determined by the urine toxicology test.
- Participants with a history of prior TMS therapy or use of an investigational drug within 12 weeks of visit
Other illness
- Participants reporting significant head trauma or serious brain illness.
- Participants with major psychiatric illness that would preclude completion of study measures. Participants with diagnosis of a psychotic or bipolar illness with be excluded.
- Participants with a history of serious medical illness, stroke, seizures, epileptiform EEG abnormalities, or family history of epilepsy.
- Participants taking any medication that may increase their risk of seizures.
- Participants with a history of substance or alcohol abuse or dependence in the past 6 months.
- Participants with a history of metalworking or injury by shrapnel or metallic objects.
Other
- Participants unable to provide signed informed consent.
- Participants with a significant risk of suicide or a h/o suicide attempt in the last 6 months. Participants with active suicidal ideation will be excluded from the study.
- Females of known/suspected pregnancy or who test positive on a pregnancy test.
- Participants with an IQ below 80 (as confirmed by the WASI, Wechsler Abbreviated Scale of Intelligence)
Who the study is looking for
- Individuals from Yale University and the surrounding community who are between the ages of 18 and 40 years old with or without a diagnosis of depression. Or individuals between the ages of 18 and 40 years old with a diagnosis of autism spectrum disorder, autistic disorder, PDD NOS, or Asperger syndrome with or without a diagnosis of depression.
- A depression score on the HDRS-17 of at least 20 will be used as a cut-off for depression.
- Participants are unmedicated or on stable medication treatment for at least two weeks.
- Willingness and ability to participate in an EEG and eye-tracking procedure.
- Provision of signed and dated informed consent.
Age in the registry: 18 years to 40 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yale Psychiatric Hospital Coordinator of this site? Confirm its status | New Haven | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.